S. Gandini, F. Sera, and M. Cattaruzza, Meta-analysis of risk factors for cutaneous melanoma: II

E. Ghissassi, F. Baan, R. Straif, and K. , A review of human carcinogens???Part D: radiation, The Lancet Oncology, vol.10, issue.8, pp.751-752, 2009.
DOI : 10.1016/S1470-2045(09)70213-X

V. Institut-de and . Sanitaire, Le bronzage artificiel: une menace bien réelle, mais évitable, pour la santé publique [Internet], Bulletin Epidémiologique Hebdomadaire, p.2012

G. Boland and J. Gershenwald, Sentinel Lymph Node Biopsy in Melanoma, The Cancer Journal, vol.18, issue.2, pp.185-191
DOI : 10.1097/PPO.0b013e31825046c7

C. Gannon, D. Rousseau, . Jr, and M. Ross, Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma, Cancer, vol.6, issue.11, pp.2647-2652, 2006.
DOI : 10.1016/S0039-6060(98)70121-7

E. Joseph, A. Brobeil, and F. Glass, Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes, Annals of Surgical Oncology, vol.21, issue.2, pp.119-125, 1998.
DOI : 10.1001/archsurg.1992.01420040034005

J. Gershenwald, M. Colome, and J. Lee, Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma., Journal of Clinical Oncology, vol.16, issue.6, pp.2253-2260, 1998.
DOI : 10.1200/JCO.1998.16.6.2253

C. Scoggins, R. Martin, and M. Ross, Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients, Annals of Surgical Oncology, vol.14, issue.3, pp.709-717, 2010.
DOI : 10.1001/archsurg.1992.01420040034005

L. Multicenter-selective and I. Trial, MSLT-II) -Full Text View -ClinicalTrials.gov [Internet]

J. Thomas, J. Newton-bishop, A. Hern, and R. , Excision Margins in High-Risk Malignant Melanoma, New England Journal of Medicine, vol.350, issue.8
DOI : 10.1056/NEJMoa030681

D. Khayat, O. Rixe, and G. Martin, Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick), Cancer, vol.97, issue.8, pp.1941-1946, 2003.
DOI : 10.1002/cncr.11272

C. Garbe, K. Peris, and A. Hauschild, Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline, European Journal of Cancer, vol.46, issue.2, pp.270-283, 2010.
DOI : 10.1016/j.ejca.2009.10.032

S. Huilgol, D. Selva, and C. Chen, Surgical Margins for Lentigo Maligna and Lentigo Maligna Melanoma, Archives of Dermatology, vol.140, issue.9, pp.1087-1092, 2004.
DOI : 10.1001/archderm.140.9.1087

M. Moncrieff, R. Martin, O. Brien, and C. , Adjuvant Postoperative Radiotherapy to the Cervical Lymph Nodes in Cutaneous Melanoma: Is There Any Benefit for High-Risk Patients?, Annals of Surgical Oncology, vol.81, issue.11, pp.3022-3027, 2008.
DOI : 10.1245/s10434-008-0087-8

B. Beadle, B. Guadagnolo, and M. Ballo, Radiation Therapy Field Extent for Adjuvant Treatment of Axillary Metastases From Malignant Melanoma, International Journal of Radiation Oncology*Biology*Physics, vol.73, issue.5, pp.1376-1382, 2009.
DOI : 10.1016/j.ijrobp.2008.06.1910

B. Burmeister, M. Smithers, B. Burmeister, and E. , A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma???Trans Tasman Radiation Oncology Group (TROG) Study 96.06, Radiotherapy and Oncology, vol.81, issue.2, pp.136-142, 2006.
DOI : 10.1016/j.radonc.2006.10.001

K. Ang, L. Peters, and R. Weber, Postoperative radiotherapy for cutaneous melanoma of the head and neck region, International Journal of Radiation Oncology*Biology*Physics, vol.30, issue.4, pp.795-798, 1994.
DOI : 10.1016/0360-3016(94)90351-4

B. Burmeister, M. Henderson, and A. J. , Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial, The Lancet Oncology, vol.13, issue.6, pp.589-597
DOI : 10.1016/S1470-2045(12)70138-9

D. Chang, R. Amdur, and C. Morris, Adjuvant radiotherapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.4, pp.1051-1055, 2006.
DOI : 10.1016/j.ijrobp.2006.05.056

L. Serrone, M. Zeuli, and F. Sega, Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview, J Exp Clin Cancer Res, vol.19, pp.21-34, 2000.

M. Avril, S. Aamdal, and J. Grob, Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study, Journal of Clinical Oncology, vol.22, issue.6, pp.1118-1125, 2004.
DOI : 10.1200/JCO.2004.04.165

M. Middleton, J. Grob, and N. Aaronson, Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma, Journal of Clinical Oncology, vol.18, issue.1, pp.158-166, 2000.
DOI : 10.1200/JCO.2000.18.1.158

U. Veronesi, J. Adamus, and C. Aubert, A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous Melanoma, New England Journal of Medicine, vol.307, issue.15, pp.913-916, 1982.
DOI : 10.1056/NEJM198210073071503

G. Hill, S. Moss, and F. Golomb, DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040, Cancer, vol.20, issue.11, pp.2556-2562, 1981.
DOI : 10.1002/1097-0142(19810601)47:11<2556::AID-CNCR2820471107>3.0.CO;2-J

C. Karakousis and L. Emrich, Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG, Journal of Surgical Oncology, vol.1, issue.4, pp.235-238, 1987.
DOI : 10.1001/archsurg.1980.01380060021006

R. Fisher, W. Terry, and R. Hodes, Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial, Surgical Clinics of North America, vol.61, issue.6, pp.1267-1277, 1981.
DOI : 10.1016/S0039-6109(16)42582-X

G. Dunn, J. Lewis, . Jr, and J. Sunwoo, Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia, Head & Neck, vol.93, issue.2, pp.267-272, 2008.
DOI : 10.1111/j.1440-0960.1997.tb01013.x

F. Azimi, R. Scolyer, and P. Rumcheva, Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma, Journal of Clinical Oncology, vol.30, issue.21, pp.2678-2683
DOI : 10.1200/JCO.2011.37.8539

J. Baurain, P. Van-der-bruggen, and B. Van-den-eynde, General principles and first clinical trials of therapeutic vaccines against cancer], Bull Cancer, vol.95, pp.327-335, 2008.

F. Jotereau, N. Labarriere, and N. Gervois, [Passive immunotherapy of melanoma], Bull Cancer, vol.90, pp.583-586, 2003.

V. Sondak, P. Liu, and R. Tuthill, Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group, Journal of Clinical Oncology, vol.20, issue.8, pp.2058-2066, 2002.
DOI : 10.1200/JCO.2002.08.071

M. Wallack, M. Sivanandham, and C. Balch, Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial, Journal of the American College of Surgeons, vol.187, issue.1, pp.69-77, 1998.
DOI : 10.1016/S1072-7515(98)00097-0

P. Hersey, A. Coates, and W. Mccarthy, Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial, Journal of Clinical Oncology, vol.20, issue.20, pp.4181-4190, 2002.
DOI : 10.1200/JCO.2002.12.094

P. Livingston, G. Wong, and S. Adluri, Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside., Journal of Clinical Oncology, vol.12, issue.5, pp.1036-1044, 1994.
DOI : 10.1200/JCO.1994.12.5.1036

J. Kirkwood, J. Ibrahim, and J. Sosman, High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801, Journal of Clinical Oncology, vol.19, issue.9, pp.2370-2380, 2001.
DOI : 10.1200/JCO.2001.19.9.2370

A. Khammari, J. Nguyen, and M. Pandolfino, Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.12, issue.3, pp.1853-1860, 2007.
DOI : 10.4049/jimmunol.173.12.7125

B. Dréno, J. Nguyen, and A. Khammari, Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.539-546, 2002.
DOI : 10.1007/s00262-002-0315-1

S. Bracarda, A. Eggermont, and J. Samuelsson, Redefining the role of interferon in the treatment of malignant diseases, European Journal of Cancer, vol.46, issue.2, pp.284-297, 2010.
DOI : 10.1016/j.ejca.2009.10.013

J. Kirkwood, M. Strawderman, and M. Ernstoff, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684., Journal of Clinical Oncology, vol.14, issue.1, pp.7-17, 1996.
DOI : 10.1200/JCO.1996.14.1.7

K. Wheatley, N. Ives, and B. Hancock, Does adjuvant interferon-?? for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials, Cancer Treatment Reviews, vol.29, issue.4, pp.241-252, 2003.
DOI : 10.1016/S0305-7372(03)00074-4

A. Eggermont, S. Suciu, and A. Testori, Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991, European Journal of Cancer, vol.48, issue.2, pp.218-225
DOI : 10.1016/j.ejca.2011.09.028

P. Adjuvant and . Intron, Ulcerated Melanoma -Full Text View -ClinicalTrials.gov [Internet]

D. Alexandrescu, T. Ichim, and N. Riordan, Immunotherapy for Melanoma: Current Status and Perspectives, Journal of Immunotherapy, vol.33, issue.6, pp.570-590, 2010.
DOI : 10.1097/CJI.0b013e3181e032e8

A. Tarhini, E. Lo, and D. Minor, Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors, Cancer Biotherapy & Radiopharmaceuticals, vol.25, issue.6, pp.601-613, 2010.
DOI : 10.1089/cbr.2010.0865

F. Hodi, O. Day, S. Mcdermott, and D. , Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010.
DOI : 10.1056/NEJMoa1003466

C. Robert, L. Thomas, and I. Bondarenko, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2526, 2011.
DOI : 10.1056/NEJMoa1104621

H. Chong, H. Vikis, and K. Guan, Mechanisms of regulating the Raf kinase family, Cellular Signalling, vol.15, issue.5, pp.463-469, 2003.
DOI : 10.1016/S0898-6568(02)00139-0

P. Chapman, A. Hauschild, and C. Robert, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011.
DOI : 10.1056/NEJMoa1103782

A. Hauschild, J. Grob, and L. Demidov, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, p.2012, 2012.
DOI : 10.1016/S0140-6736(12)60868-X

K. Flaherty, C. Robert, and P. Hersey, Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [Internet], The New England Journal of Medicine, p.2012, 2012.

I. Ph and . Ii, Ipilimumab Vemurafenib Combo -Full Text View -ClinicalTrials.gov [Internet], 2012.

J. Grob, B. Dreno, and P. De-la-salmonière, Randomised trial of interferon ??-2a as adjuvant therapy in resected primary melanoma thicker than 1??5 mm without clinically detectable node metastases, The Lancet, vol.351, issue.9120, pp.1905-1910, 1998.
DOI : 10.1016/S0140-6736(97)12445-X

A. Eggermont, S. Suciu, and M. Santinami, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial, The Lancet, vol.372, issue.9633, pp.117-126, 2008.
DOI : 10.1016/S0140-6736(08)61033-8

URL : https://hal.archives-ouvertes.fr/hal-00485095

C. Lévy-sitbon, C. Barbe, and F. Granel-brocard, Diagnosis and management of melanoma with regional lymph node metastases: a population-based study in France, Journal of the European Academy of Dermatology and Venereology, vol.372, issue.Suppl 5, p.201222845015, 2012.
DOI : 10.1016/S0140-6736(08)61033-8

L. Uwer, S. Martin, and L. Geoffrois, Faisabilit?? et tol??rance du traitement adjuvant des m??lanomes par immunoth??rapie selon le protocole de Kirkwood, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.1, pp.50-51, 2005.
DOI : 10.1016/S0151-9638(05)79199-7